Seegene USA gets EUA for HSV, VZV, mpox assay
July 23, 2026—Seegene USA has received FDA emergency use authorization for the Allplex HSV-1&2/VZV/MPXV assay.
Webinars and Sponsored Roundtables — Register Now
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Cepheid to unveil third-generation GeneXpert at ADLM 2026
July 22, 2026—Cepheid will unveil the third generation of the GeneXpert system on Tuesday, July 28, at the Association for Diagnostics and Laboratory Medicine Annual Scientific Meeting.
FSP 5th Multidisciplinary Interactive Precision Medicine Symposium
July 21, 2026—The Florida Society of Pathologists 5th Multidisciplinary Interactive Precision Medicine Symposium will take place Aug. 22 at Moffitt Cancer Center, 12902 USF Magnolia Drive, in Tampa, Fla.
Zepto introduces FungiFlex Pneumocystis jirovecii, Mold Plus tests
July 20, 2026—Zepto Life Technology has introduced FungiFlex Pneumocystis jirovecii, a targeted plasma cell-free DNA liquid biopsy assay for the detection of P. jirovecii, and the FungiFlex Mold Plus panel, which combines invasive mold detection with P. jirovecii in a single plasma-based test order.
Leica Biosystems to acquire StatLab Medical Products
July 15, 2026—Leica Biosystems, an operating company of Danaher, has entered into a definitive agreement to acquire privately held StatLab Medical Products, a global developer and manufacturer of anatomic pathology products, from Linden Capital Partners and Audax Private Equity. Following the closing, StatLab will become part of Leica Biosystems. StatLab provides a broad portfolio of products across the preanalytical and analytical histology workflow, from specimen collection and tissue processing through slide preparation and staining. Built on a strong reputation for
Seegene launches Global Million Clinical Study
July 10, 2026—Seegene has launched the Global Million Clinical Study, which aims to evaluate the clinical utility and potential impact of syndromic PCR testing using real-world data.
FDA clears Visby’s at-home multiviral PCR test
July 9, 2026—The FDA has cleared the Visby Medical Flu and COVID-19 at-home PCR test.
Bio-Rad launches Vericheck ddPCR kits for QX700 platform
July 7, 2026—Bio-Rad Laboratories launched its QX700 system-compatible Vericheck ddPCR kit portfolio for quality control workflows in advanced cell and gene therapy development and other biopharma applications.
Epredia launches SlideMate thermal slide printer
July 6, 2026—Epredia has launched sales of the SlideMate thermal slide printer, engineered to help clinical laboratories protect tissue samples, strengthen sample traceability, and streamline workflow efficiency during cancer diagnosis.
Versant expands collaboration with Leica Biosystems
June 30, 2026—Leica Biosystems and Versant Diagnostics are expanding their collaboration to advance digital pathology adoption.